



Melior Enters Drug Discovery Collaboration with Rett Syndrome Research Trust

March 30, 2010, Exton, PA – Melior Discovery, Inc. announced today that it has entered into a collaboration with the Rett Syndrome Research Trust to screen drug-candidates in an *in vivo* model of Rett Syndrome.

Melior Discovery has developed world-class expertise in screening compounds for potential therapeutic activity in animal models. Melior will apply this expertise to the evaluation of large numbers of drug-candidates in a specialized model of Rett Syndrome. “This partnership is further illustration of Melior’s truly unique capabilities and competence in high throughput *in vivo* pharmacology” said Andrew Reaume PhD, CEO, Melior Discovery.

Rett Syndrome, the most physically disabling of the autism spectrum disorders, strikes young girls almost exclusively, with first symptoms usually appearing before the age of 18 months. These children lose speech, motor control and functional hand use, and many suffer from seizures, orthopedic and severe digestive problems, breathing and other autonomic impairments. Most live into adulthood, and require total, around-the-clock care.

The disorder is caused by alterations of an X-linked gene, *MECP2*. The animal models that have been developed mimic the disorder well and provide an excellent system to test potential drug candidates.

“We are pleased to be working with Melior and have been impressed with their ability to rapidly and effectively evaluate compounds in animal models. We look forward to our collaboration as we strive to identify compounds to ameliorate the devastating symptoms of Rett,” added Monica Coenraads, Executive Director of the Rett Syndrome Research Trust.

About Melior Discovery, Inc.

Melior Discovery is leading the transformation of pharmaceutical drug repositioning with its unique *theraTRACE*[®] platform of multiplexed *in vivo* models. Melior is using this capability to build an internal pipeline of development candidates. Melior Discovery also partners with pharmaceutical and biopharmaceutical companies to expand their drug development pipelines by using the *theraTRACE*[®] platform, and individual animal models, in conjunction with the Company’s in-depth *in vivo* pharmacology expertise.

Melior Discovery is located in Exton, PA. The Company is privately held with investors that include Cammeby’s Capital Group, VenturEast, Osage Ventures, Mid-Atlantic Angel Group, and BioAdvance.



About the Rett Syndrome Research Trust

The Rett Syndrome Research Trust is a nonprofit research organization formed in the wake of the dramatic pre-clinical reversal of Rett Syndrome symptoms. The Trust is intensively focused on the development of treatments and cures for Rett Syndrome and related *MECP2* disorders. To learn more about the Trust please visit

www.reverserett.org

For more information contact:

Andrew Reaume, Ph.D MBA
President and CEO
Melior Discovery

(+1) 610-280-0633 ext 239

e-mail: areaume@meliordiscovery.com

Monica Coenraads, MBA
Executive Director
Rett Syndrome Research Trust
(+1) 203-445.0041
monica@rsrt.org